Renal Denervation Market, By Product (Simplicity Renal Denervation System, Enlightn, Vessix Renal Denervation System, Paradise Renal Denervation System and Iberis Renal Sympathetic Denervation System), By Application (Radiofrequency, Ultrasound, And Micro-Infusion), By End User (Hospitals, Surgical Centers and Clinics) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) – Trends, Analysis, and Forecast till 2034

Report Code: PMI111519 | Publish Date: February 2024 | No. of Pages: 180

Global Renal Denervation Market By Overview

Renal Denervation Market was valued at US$ 2.6 billion in 2024 and is projected to grow at a CAGR of 38.4% to reach US$ 50.1 billion by 2034.

A minimally pain, catheter based endovascular procedure which uses radiofrequency ablation or ultrasound ablation to treat resistant hypertension is known renal denervation. Renal denervation is a minimal invasive procedure to treat hypertension which process by causing reduction in nerve activity which decreases blood pressure. Renal artery contains nerves in their wall which are ablated by applying radiofrequency pulses or ultrasound to the renal arteries. High blood pressure which is not treated by medication are resistant hypertension. The development of catheter-based interventional therapies to ablate renal nerve has shown impressive results in treating blood pressure in patients having complaints of resistant hypertension. 

Renal Denervation Market - Introduction

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Global Renal Denervation Market By Drivers & Restraints

Increase in prevalence of hypertension

Increase in prevalence of hypertension, blood pressure, changing lifestyle of the people, improvement of healthcare infrastructure in developing countries, such as micro-infusion, for renal denervation systems are the main driving factors for the growth of the global market. 

High blood pressure

High blood pressure increases the risk of stroke and heart disease, a leading cause of deaths all over the globe and complication of hypertension, death due to stroke; heart failure are anticipated to fuel the target market growth. Increasing cases of uncontrolled and drug-resistant hypertension are expected to fuel the demand for renal denervation. However, stringent regulatory norms and approval process for renal denervation devices and patience discomfort and pain that arises during reimbursements for renal denervation procedure have inhibited the target market growth.

Global Renal Denervation Market By Segmentations & Regional Insights

The renal denervation market is segmented on the basis of application, product, end user and Region.

On the basis of product, global renal denervation market is segmented into simplicity renal denervation system, EnligHTN, vessix renal denervation system, paradise renal denervation system, and iberis renal sympathetic denervation system. On the basis of application, the target market is classified into radiofrequency, ultrasound, and micro-infusion.  On the basis of end user, the target market is classified into hospitals, surgical centers and clinics.

Regional Insights:

Renal Denervation Market - Regional Insights

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

On the basis of region, global renal denervation market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Europe’s high share is attributed to the early start of this technology in European countries due to large consumption of the target market. North America accounts for a small proportion as renal denervation systems are available only for investigational purpose in the North American market and are not approved by some organzations. Asia-Pacific is expected to grow at the fastest rate during the analysis period, owing to presence of ample growth opportunities in terms of unmet medical needs for the treatment and use of advanced technologies such as renal denervation systems, and high prevalence rate of resistant hypertension.

Report Scope:

Attribute

Details

Market Size 2024

US$ 2.6 billion

Projected Market Size 2034

US$ 50.1 billion

CAGR Growth Rate

38.4%

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Product - Simplicity Renal Denervation System, Enlightn, Vessix Renal Denervation System, Paradise Renal Denervation System and Iberis Renal Sympathetic Denervation System.

By Application - Radiofrequency, Ultrasound, And Micro-Infusion

By End User - Hospitals, Surgical Centers and Clinics

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Renal Denervation Market, By Product:

  • Simplicity Renal Denervation System
  • Enlightn
  • Vessix Renal Denervation System
  • Paradise Renal Denervation System
  • Iberis Renal Sympathetic Denervation System

Renal Denervation Market, By Application:

  • Radiofrequency
  • Ultrasound
  • Micro-Infusion

Renal Denervation Market, By End-User:

  • Hospitals
  • Surgical Centers
  • Clinics

Renal Denervation Market, By Region:

  • North America
    • Middle East & Africa
      • Middle East & Africa Renal Denervation Market, By Product
      • Middle East & Africa Renal Denervation Market, By Application
      • Middle East & Africa Renal Denervation Market, By End-User
      • Middle East & Africa Renal Denervation Market, By Country
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
      • Latin America Renal Denervation Market, By Product
      • Latin America Renal Denervation Market, By Application
      • Latin America Renal Denervation Market, By End-User
      • Latin America Renal Denervation Market, By Country
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
      • Asia Pacific Renal Denervation Market, By Product
      • Asia Pacific Renal Denervation Market, By Application
      • Asia Pacific Renal Denervation Market, By End-User
      • Asia Pacific Renal Denervation Market, By Country
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Europe
      • Europe Renal Denervation Market, By Product
      • Europe Renal Denervation Market, By Application
      • Europe Renal Denervation Market, By End-User
      • Europe Renal Denervation Market, By Country
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • North America Renal Denervation Market, By Product
    • North America Renal Denervation Market, By Application
    • North America Renal Denervation Market, By End-User
    • North America Renal Denervation Market, By Country
      • The U.S.
      • Canada

Global Renal Denervation Market By Competitive Landscape & Key Players

 The key players in renal denervation market are Ablative Solutions, Inc., Boston Scientific Corporation, Cardiosonic Ltd, Kona Medical, Inc., Medtronic plc pvt Lt, Mercator Med Systems, Inc., ReCor Medical, Inc., Renal Dynamics Limited, St. Jude Medical, Inc., and Terumo Medical Corporation. For instance, In December 2020, ReCor Medical Announces Positive Results in RADIANCE-HTN TRIO Study and Breakthrough Device Designation for Paradise Ultrasound Renal Denervation System. In March 2020, Medtronic plc has announced the first-ever clinical data from the SPYRAL HTN-OFF MED Pivotal Trial. The Landmark SPYRAL HTN-OFF MED Pivotal Trial Shows Superiority for Renal Denervation in Patients with High Blood Pressure Compared to Sham Procedure.

Global Renal Denervation Market By Recent News

Recent Developments:

  • In December 2023: The Symplicity Spyral renal denervation system (RDN) has been made available by Medtronic plc as a treatment for excessive blood pressure. After 10 years of clinical research and development, Medtronic recently revealed that the system has received approval from both the US Food and Drug Administration (FDA) and Indian regulatory bodies.
  • In December 2023: The first FDA-approved renal denervation therapy in the United States, Recor's Paradise Ultrasound Renal Denervation (uRDN) system, is now being used commercially for the treatment of hypertension, according to Recor Medical, Inc. and its parent firm, Otsuka Medical Devices Co., Ltd. The NewYork-Presbyterian/Columbia University Irving Medical Center in New York City performed the first commercial procedures.

Global Renal Denervation Market By Company Profile

  • Ablative Solutions, Inc.
    • Company Overview
    • Financial Performance
    • Key Highlights
    • Product Portfolio
  • Boston Scientific Corporation
    • Company Overview
    • Financial Performance
    • Key Highlights
    • Product Portfolio
  • Cardiosonic Ltd
    • Company Overview
    • Key Highlights
    • Financial Performance
    • Product Portfolio
  • Kona Medical, Inc.
    • Company Overview
    • Financial Performance
    • Key Highlights
    • Product Portfolio
  • Medtronic plc pvt Ltd
    • Company Overview
    • Financial Performance
    • Key Highlights
    • Product Portfolio
  • Mercator Med Systems, Inc.
    • Company Overview
    • Financial Performance
    • Key Highlights
    • Product Portfolio
  • Meril Life Science Pvt. Ltd.
    • Company Overview
    • Financial Performance
    • Key Highlights
    • Product Portfolio
  • ReCor Medical, Inc.
    • Company Overview
    • Financial Performance
    • Key Highlights
    • Product Portfolio
  • Renal Dynamics Limited
    • Company Overview
    • Financial Performance
    • Key Highlights
    • Product Portfolio
  • St. Jude Medical, Inc.
    • Company Overview
    • Financial Performance
    • Key Highlights
    • Product Portfolio
  • Terumo Medical Corporation
    • Company Overview
    • Financial Performance
    • Key Highlights
    • Product Portfolio

FAQs

The renal denervation market is segmented on the basis of application, product, end user and Region.

Increase in prevalence of hypertension, blood pressure, changing lifestyle of the people, are the main driving factors for the growth of the global market.

Europe’s high share is attributed to the early start of this technology in European countries due to large consumption of the target market.

The key players in renal denervation market are Ablative Solutions, Inc., Boston Scientific Corporation, Cardiosonic Ltd, Kona Medical, Inc., Medtronic plc pvt Lt, Mercator Med Systems, Inc., ReCor Medical, Inc., Renal Dynamics Limited, St. Jude Medical, Inc., and Terumo Medical Corporation.